WellTheory Announces Women’s Health Program to Address Hormonal Conditions
WellTheory has launched a new program that will address the link between autoimmune disease and hormone imbalances.
Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug
The Teva Pharmaceuticals and Sanofi drug, duvakitug, showed statistically significant and clinically meaningful results in a Phase 2b study in ulcerative colitis and Crohn’s disease. The drug is part of an emerging class of therapies that target TL1A, a protein involved in signaling that drives inflammation.
The Future of Men’s Healthcare: A Path to Improved Access, Outcomes, and Cost Savings
Telehealth empowers men to take control of their health in a way that is easy, confidential, and fits into their busy lifestyles.
Let’s Rethink AI — Patient Intake Is the Perfect Place to Start
Solutions like AI-powered patient intake offer a tangible ROI by streamlining administrative tasks, reducing errors, and improving care quality.
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder
Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million.